Xenon Pharmaceuticals XENE unveils its next round of earnings Wednesday. Get prepared with Benzinga's ultimate preview for Xenon Pharmaceuticals' Q4 earnings.
Earnings and Revenue
Analysts covering Xenon Pharmaceuticals have modeled for quarterly EPS loss of 11 cents on revenue of $6.28 million.
Xenon Pharmaceuticals reported a loss of 32 cents per share when it published results during the same quarter last year. Sales in that period totaled $376,000. If the company were to report inline earnings when it publishes results Wednesday, quarterly profit would be up 65 percent.
Here's how the company's EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.08 | -0.39 | -0.38 | -0.42 |
| EPS Actual | -0.43 | -0.41 | -0.43 | -0.32 |
Stock Performance
Over the last 52-week period, shares are down 53.78 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The most common rating by analysts on Xenon Pharmaceuticals stock is a Buy. The strength of this rating has maintained conviction over the past three months.
Conference Call
Xenon Pharmaceuticals's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
